LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Maternal Lipid Profile Tied to Pediatric CHD Risk

By LabMedica International staff writers
Posted on 25 Sep 2021
Print article
The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott)
The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott)
Congenital heart disease (CHD among live births, is the major form of birth defect and the leading cause of childhood mortality with an incidence of 9.1‰. The occurrence of CHD is caused by many factors.

With the improvement in living standards and an increasing number of women with advanced maternal age, there is an increase in the prevalence of chronic metabolic diseases, such as obesity, diabetes, hypertension, and hyperlipidemia, among pregnant women.

Clinical Scientists at the Children's Hospital of Fudan University (Shanghai, China) carried out a single-center case–control study that included 230 mothers of offspring with CHD and 381 without CHD. Maternal lipid levels were determined on fasting blood samples taken in the first trimester. Relevant demographic and clinical data were extracted from the medical records. Maternal lipid profile was compared between the two groups, and regression analysis was performed to evaluate the association between lipid profile and CHD risk in offspring.

Fasting peripheral blood samples were collected between eight and 14 weeks of gestation. Folic acid, vitamin B12, thyroid abnormality, homocysteine (Hcy), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), free fatty acid, Apolipoprotein-A1 (Apo-A1), Apolipoprotein-B (Apo-B), fasting blood glucose, and hemoglobin A1c (HbA1c) were all measured. TG, TC, HDL-C, LDL-C, free fatty acid, Apo-A1, Apo-B, and fasting blood glucose were analyzed by an automatic biochemical analyzer (Hitachi 7180, Tokyo, Japan) using commercially available kits. Folic acid and vitamin B12 were measured using the Architect i2000chemiluminescence immunoassay analyzer (Abbott, Lake Forest, IL, USA). Serum Hcy measurements were carried out by Liquid Chromatography Coupled to Tandem Mass Spectrometry (LC/MS/MS) using an API 3000 LC/MS/MS system (Applied Biosystems, Waltham, MA, USA).

The investigators reported that compared with the control group, levels of triglyceride, apolipoprotein-A1, and apolipoprotein-B in early pregnancy were significantly higher in the CHD group. Multivariate analyses showed that triglyceride (odds ratio [OR] 2.46), total/high-density lipoprotein cholesterol (OR 2.10), and apolipoprotein-A1 (OR 2.73), were positively associated with CHD risk in offspring. Each lipid biomarker was associated with an almost twofold increased risk of CHD, independent of HbA1c and Hcy.

The authors concluded that mild dyslipidemia in early pregnancy was closely associated with the occurrence of CHD in offspring. In combination with previous studies, it is possible that lipid metabolism in early pregnancy may influence the outcome of pregnancy. The study was published on August 3,2021 in the journal Acta Obstetricia et Gynecologica Scandinavica.

Related Links:

Children's Hospital of Fudan University
Hitachi 
Abbott
Applied Biosystems

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more